Alnylam Says European RNAi Patent Invalidated | GenomeWeb

NEW YORK (GenomeWeb News) - Alnylam Pharmaceuticals this week announced that the European Patent Office has overturned the claims of one of its patents covering compositions, methods, and uses of siRNAs between 15 and 49 nucleotides long.

The patent in question, EP 1214945, is part of Alnylam's so-called Kreutzer-Limmer patent estate, which the company acquired when it bought German RNAi shop Ribopharma in 2003.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.